Device Management in HFpEF and HFmrEF: Insights From the REDUCE LAP-HF II Trial
Published: 24 January 2022
-
Views:
9375
-
Likes:
7
-
Views:
9375
-
Likes:
7
Overview
HF with preserved ejection fraction (HFpEF) remains an unmet need, however new therapeutic strategies are emerging to improve quality of life and clinical outcomes. Although medical therapy is the cornerstone of treatment for individuals with EF ≥40%, there is a considerable need for approaches that extend these benefits to individuals who remain symptomatic following medical therapy.
The following videos aim to educate physicians in the changing landscape of the device management of HFpEF.
This programme was supported by an unrestricted educational grant from Corvia Medical
Learning Objectives
- Explain the clinical rationale behind an atrial shunt in HFpEF
- Recall overall and pre-specified sub-group results from the REDUCE LAP-HF II trial
- Describe the clinical features of likely responders and non-responders to an atrial shunt
- Identify which HFpEF patients are likely to benefit from the use of an atrial shunt
- Discuss the utility of cardiac interventions for the future treatment of HFpEF
Target Audience
- Heart Failure Specialists
- General Cardiologists
More from this programme
Part 1
Data Presentation
Dr Barry Borlaug presents a brief overview of the device and how it gains benefit in HFpEF.
Part 2
Roundtable Discussion
Prof Andrew Coats, Dr Barry Borlaug, Dr Sanjiv Shah and Prof Gerd Hasenfuß review the trial findings and discuss what the data means to the HF community and the wider cardiovascular community, alongside discussing why this data is important.
